Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast cancer surgery: Study finds overnight hospital stay not important for older patients

2.

GLP-1 drugs linked to dramatically lower death rates in colon cancer patients

3.

Coffee and tea linked to lower head and neck cancer risk

4.

Achieves a High Disease Control Rate in Head and Neck BCC with Vismodegib-RT Regimen.

5.

Clinical Evidence Shows Venetoclax Combo Is Safe and Effective in AML Patients 80 Years of Age and Up.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot